Related Quotes Sym. Price Chg. ACTC Trade News 0.825 0.035 WiCell Research Institute and Advanced Cell Technology Offer to Distribute New Stem Cell Lines to U.S. Researchers; Agreement Subject to U.S. Federal Government Recognition and Funding of Cell Lines
September 12, 2006 10:48:07 (ET)
MADISON, Wis. and ALAMEDA, Ca., Sep 12, 2006 (BUSINESS WIRE) -- The WiCell Research Institute (WiCell) and Advanced Cell Technology (ACTC, Trade) announced today an agreement, in principle, to collaborate to jointly distribute to U.S. scientists a range of new cell lines. These stem cell lines would be produced using a recently announced technique in the peer-reviewed journal Nature, provided that the United States federal government recognizes these new lines and funds research utilizing them. Under their collaboration, agreed in principle between the parties, Advanced Cell Technology and WiCell hope to make the new stem cell lines readily available to U.S. scientists for medical research.
In its role as the National Stem Cell Bank, WiCell has taken a leadership role in providing cells to academic researchers by providing a free license and training to scientists interested in pursuing this new technology. More than 350 academic research groups are working with cells from WiCell. Under the agreement in principle, WiCell, a subsidiary of the Wisconsin Alumni Research Foundation (WARF), would distribute stem cell lines derived from Advanced Cell Technology's proprietary method, if approved by the President and the National Institutes of Health.
"Provided that the federal government is willing to fund future human embryonic stem cell research where it can be demonstrated that the embryo was not harmed, we will do our part in scaling up many new lines under Good Manufacturing Processes (GMP) guidelines and making such lines available," stated William M. Caldwell, IV., Chief Executive Officer of Advanced Cell Technology. "We are well aware of the impact that delays in advancing new therapies can have on people in need of therapy and provided that the federal government advances legislation in an expeditious manner, we will make the derivation of new lines a company priority."
"Advanced Cell Technology's development is very encouraging," stated Elizabeth Donley, Executive Director of WiCell. "We are hopeful that future human embryonic stem cells created by this new process can be approved for federal funding. Increasing the number of federally funded stem cell lines is essential for speeding the development of this important technology to treat many of human kind's most serious diseases and injuries. WiCell has agreements to distribute 13 of the 21 lines currently available on the National Institutes of Health Registry. We will continue our effort to provide all lines that are eligible for federal funding."
About the WiCell Research Institute
The WiCell Research Institute is dedicated to expanding the frontiers of science and medicine by unlocking the potential of stem cells. As a subsidiary of the Wisconsin Alumni Research Foundation and a supporting organization of the University of Wisconsin-Madison, WiCell conducts research, supports research at UW-Madison, hosts the National Stem Cell Bank, provides training for scientists, and offers educational outreach programs for K-12 students and the community.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
For Advanced Cell Technology: FD, Healthcare & Life Sciences Robert Stanislaro, 212-850-5657 or For Wisconsin Alumni Research Foundation: Andy Cohn, 608-263-2821 Copyright Business Wire 2006
Posted by IMAKEMONEY on :
Related Quotes Sym. Price Chg. ACTC Trade News 0.855 0.105 Advanced Cell Technology Reports Visual Function Rescue in Animals Utilizing Human Embryonic Stem Cell-Derived Retinal Cells; Transplanted Cells Shown Capable of Rescuing Photoreceptor Cells in RCS Rats with Retinal Disease
September 21, 2006 07:00:34 (ET)
WORCESTER, Mass., Sep 21, 2006 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (OTCBB: ACTC.OB) today announced that company scientists and their collaborators rescued visual function in rats through implantation of retinal pigment epithelial cells (RPE) derived from human embryonic stem (hES) cells. The study results were reported in a paper entitled "Human Embryonic Stem Cell-Derived Cells Rescue Visual Function in Dystrophic RCS Rats" published online today ahead of print in the Fall 2006 issue of the journal Cloning and Stem Cells.
In a series of several experiments, researchers generated RPE cells from 18 different hES cell lines. Cells derived from one of the NIH-approved cell lines were injected into RCS rats in an attempt to compensate for the photoreceptor cell loss caused by a genetic trait carried by such RCS rats. These animals lose their photoreceptor cells over several months following birth and are used to study conditions under which this loss, similar to that occurring in macular degeneration, can be prevented or treated.
In the study published in Cloning and Stem Cells, rats were injected with hES- derived RPE cells into the subretinal space of the eye at 21 days after their birth, an age at which photoreceptor degeneration has not yet occurred. As controls, some rats received injections of cell culture medium alone, or were not injected. Tests for visual function were performed at 60 and 90 days after birth, times at which loss of photoreceptor cells has produced characteristic vision deficits. As more fully described in the paper, test results of relative visual acuity demonstrated that animals receiving hES-derived RPE cells performed significantly better than cell culture medium treated or untreated controls. Treated animals showed a 50 percent improvement over medium-treated controls and a 100 percent improvement over untreated controls in visual performance. Visual acuity was approximately 70 percent of normal rats.
"One important advantage offered by hES-derived cells over other cells developed to mimic or replace lost retinal pigment epithelium is that they more closely resemble primary human RPEs," stated Raymond D. Lund, Ph.D., Professor at the Moran Eye Center, University of Utah Health Science Center, Salt Lake City and the study's lead author. "Another significant advantage of using these cells is that a range of lines can be derived allowing the opportunity to 'tissue match' donor cells with recipient, a real advantage given that RPE cells are highly immunogenic and susceptible to rejection without some form of immunosuppression."
"Embryonic stem cells promise to provide a well-characterized and reproducible source of replacement cells for clinical studies," stated Robert Lanza, M.D., Vice President of Research & Scientific Development at ACTC and senior author of the paper. "All 18 human embryonic stem cell lines we studied reliably produced retinal cells that could potentially be used to treat retinal degenerative diseases, such as macular degeneration. We showed that these cells have the capacity to rescue visual function in animals that otherwise would have gone blind. Importantly, the cells did not appear to cause any unwanted pathological responses in the animals following transplantation."
"We are working to generate clinical grade RPE cells from human embryonic stem cells under controlled GMP conditions," said Irina Klimanskaya, Ph.D., Director of Stem Cell Biology at ACTC, and the author who initiated this work. "However, more research is still required to optimize their performance and to assure they are safe for clinical trials."
"We are encouraged by this data related to our retinal program and are focused on driving therapies to the clinic," stated William M. Caldwell IV, CEO of ACTC.
Other authors include Shaomei Wang, Toby Holmes, Bin Lu, N. Bischoff, and Sergej Girman of the Moran Eye Center; Rebeca Ramos-Kelsey of Advanced Cell Technology, and Yves Sauve of the Ophthalmology and Physiology Dept., University of Alberta, Edmonton.
About Advanced Cell Technology, Inc.
Advanced Cell Technology Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com..
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: FD, Healthcare and Life Sciences Robert Stanislaro, 212-850-5657 or Investors: The Investor Relations Group James Carbonara, 212-825-3210 Copyright Business Wire 2006
Posted by invester on :
I just picked up 10k. I watched ACOR go from $2-$11 in two days. This will do the same.
Posted by IMAKEMONEY on :
God that would be GREAT!!!!!!!! Posted by invester on :
Share count is about the same. When they get appropriations for the government this will be at $10. That would make it a $260m company. Look at: ASTM-$142m Company STEM-$168m company
Now look at ACTC-$19m Company. This could go to $10 VERY easy.
Posted by IMAKEMONEY on :
Im in! And thats why. Posted by invester on :
Also, I see your from San Diego, I need your Padres to beat the Cardinals tonight, and tomorrow so the Astros win there division. Can you handle that for me?
Posted by IMAKEMONEY on :
DONE!
Posted by invester on :
Sweet!!!!
Posted by Daddy Warbucks on :
Any word on when the Feds might pony up?
Posted by invester on :
None yet, but the most right winged conservatives are up for the idea if it doesn't damage the embryo. This will be up 500%+ first day when it does.
Posted by IMAKEMONEY on :
Related Quotes Sym. Price Chg. ACTC Trade News 0.69 0.05 Investor`s Business Daily Cites Advanced Cell Technology`s Scientific Leadership in Burgeoning Embryonic Stem Cell Industry
October 06, 2006 06:30:16 (ET)
ALAMEDA, Calif., Oct 06, 2006 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, today announced that the Company was prominently featured by the newspaper "Investor's Business Daily" in an in-depth article highlighting top investment opportunities in the embryonic stem cell industry.
The Investor's Business Daily (IBD) article, titled "Patience an Asset in Stem Cell Work," details the current political and ethical debates limiting federal funding for stem cell research and development. The IBD newspaper suggests that Advanced Cell Technology's (ACTC) groundbreaking science and research may help speed the development of stem cell-based cures by addressing some of these scientific and ethical debates.
ACTC recently announced that Company scientists demonstrated the ability to generate new human embryonic stem cell lines by adapting a proven technique used at in vitro fertilization labs to determine genetic health. The ACTC approach maintains the embryo's potential for life, addressing one of the key debates in stem cell research by showing it is possible to generate embryonic stem cell lines without harming embryos.
ACTC has said its non-destructive technique may help open up the federal funding and speed the development of needed stem cell-based science and breakthrough therapies, according to the IBD article.
To accelerate its development programs, the article noted that ACTC recently moved to California where "voters approved a 10-year, $3 billion stem cell research fund in 2004."
"If you're going to survive you must be close to the capital," the article quoted William Caldwell IV, Chief Executive Officer of Advanced Cell Technology.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Financial Dynamics Robert Stanislaro, 212-850-5657 (Media) or The Investor Relations Group James Carbonara, 212-825-3210 (Investors) or Financial Communications Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com Copyright Business Wire 2006
Posted by HossTrader on :
This is one of those companies in pinky land that kill me. This one is obviously legit. Tons of external verification. The magazine "Nature", IBD, etc. But at the same time being a bio-tech startup it will need tons of capital until it does hit.
The fact that I know it is legit makes me much more comfortable with the long run odds though.
Posted by invester on :
I picked up another 5000. This one will move like ACOR very soon.
Posted by Jo4321 on :
Of course it will...now that I sold it yesterday for a 69% loss.
I'm not gonna watch....I'm not gonna watch (peeking)
Jo
Posted by invester on :
Posted by IMAKEMONEY on :
HOSS, You in this one?
Posted by invester on :
Do you know this has a P/E of 2. I guess there making money? That’s amazing. Not only will this be a $10 stock as soon as the government steps in, but they are already making money. Impressive.
Posted by Repoman75 on :
It's at .65 now.. when it hits .40, I'll buy
Posted by HossTrader on :
quote:Originally posted by IMAKEMONEY: HOSS, You in this one?
I am in it just a little bit. I have maybe $1200 in it right now. This one looks to be at least a legit company, we are just betting on if they can hit the big score.
Posted by invester on :
quote:Originally posted by Repoman75: It's at .65 now.. when it hits .40, I'll buy
.40? Good luck with that. LoL.
Posted by invester on :
Just picked up another 5k. 20k total.
Posted by J_U_ICE on :
Advanced Cell Technology's Dr. Robert Lanza Will Be a Featured Speaker at the 6th Annual Stem Cells & Regenerative Medicine Meeting 10/13/2006
ALAMEDA, Calif., Oct 13, 2006 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.'s (OTCBB:ACTC) Robert Lanza, M.D., Vice President of Research & Scientific Development, will speak on "Human ESC-Derived Cells for Rescue of Visual Function and Repair of Vascular Damage," at the 6th Annual Stem Cells & Regenerative Medicine meeting October 16-17, 2006 at the Renaissance Pittsburgh Hotel in Pittsburgh, PA. Dr. Lanza will present on Monday, October 16th at 9:30 a.m. and such presentation shall be available on the company's website.
Embryonic stem cells promise to provide a well-characterized and reproducible source of replacement tissue for human clinical studies. Two early potential applications of this technology are the use of human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) for the treatment of retinal degenerative diseases such as macular degeneration and retinitis pigmentosa, and the use of hESC-derived hemangioblasts for vascular restoration of organs and limbs. Recent progress using these cells to affect substantial functional and morphological rescue in animals will be discussed.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investor Relations: James Carbonara Media Relations: Bill Douglass 212-825-3210 or Financial Communications: Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com
Copyright Business Wire 2006
Posted by IMAKEMONEY on :
Should RUN!!!!!!!!!!! Posted by IMAKEMONEY on :
ARCA IS FLIPPING!!
Posted by HossTrader on :
picked some more up at .715. This could get interesting
Posted by HossTrader on :
This should get a response from the conference. The potential of this company, and the share price just don’t add up. The market cap at $10 is only $280m. This is a 10-15 billion dollar industry by 2010, and they have a patent on the leading technology. It doesn't damage the embryo. There should be no governmental dispute. I literally could see this at $20-$30 after appropriations.
Posted by IMAKEMONEY on :
All right HOSS, Hope your right invester. IM IN!!
Posted by HossTrader on :
This is the type of pink I love to find. I can find NOTHING that makes me question that this company is actually trying to do what they say they are doing. They are conducting real research into products for a real market. It isn't just a share printing op, or another company pretending to jump on a hot topic.
That being said, there are no guarantees this company will be successful, or they won't have to raise more capital.
But at least with this one, you are gambling on them developing the technology and bringing it to market instead of gambling on wether or not the ceo is full of ****.
Posted by IMAKEMONEY on :
LOL HOSS, YEP.
Posted by invester on :
I would be buying all I can at this level.
Posted by invester on :
Major buying coming in.
Posted by IMAKEMONEY on :
YES IT IS PICKING UP, NICE Posted by invester on :
The conference is today. I know of two Inv. banks that are there, and they are starting to realize this should be a $10 stock. I have 20k shares. Posted by HossTrader on :
This is some great movement today. The conference must be going well.
Posted by invester on :
My chart says institutional money. This is really good.
Posted by invester on :
Major gap.
Posted by invester on :
3 bids at .80. This will be way over $1 soon. I told you guys to back the truck up at .61. At $10 the market cap is 280 million. This is a 10-15 billion industry by 2010.
Posted by IMAKEMONEY on :
LOOKING GOOD!!
Posted by IMAKEMONEY on :
winner!!!!!!!!
Posted by invester on :
Yes sir. This truly is the ground floor of this stock.
Posted by invester on :
quote:Originally posted by HossTrader: This is the type of pink I love to find. I can find NOTHING that makes me question that this company is actually trying to do what they say they are doing. They are conducting real research into products for a real market. It isn't just a share printing op, or another company pretending to jump on a hot topic.
That being said, there are no guarantees this company will be successful, or they won't have to raise more capital.
But at least with this one, you are gambling on them developing the technology and bringing it to market instead of gambling on wether or not the ceo is full of ****.
Also, this is not a pink, its a BB.
Posted by Schwabie on :
Advanced Cell Technology To Present Progress Report on Product Development and ACTCellerate Platform at BIO Investor Forum
Business Wire "US Press Releases "
ALAMEDA, Calif.--(BUSINESS WIRE)--
Advanced Cell Technology, Inc.'s (OTCBB:ACTC) Michael West, Ph.D., Chairman, President and Chief Scientific Officer will be presenting at the 2006 BIO Investor Forum at the Palace Hotel, in San Francisco, California on October 19, 2006. The presentation is scheduled for 2:20 PM in the Sea Cliff room. Presentation slides and a live web cast may be accessed through the company's website at www.advancedcell.com.
Dr. West will discuss ACT's recently-published data on blastomere biopsy (a novel technique that allows human ES cell lines to be produced from a single embryonic cell), thereby demonstrating the feasibility of producing new human ES cell lines without disaggregating human embryos. In addition, Dr. West will discuss recently-published positive results in preclinical studies with the company's retinal pigment epithelial (RPE)cells, and an update on ACTCellerate. As previously announced by the company, ACTCellerate is a technology platform for isolating novel purified and scalable cell types from human embryonic stem cells. New results relating to novel propagating human heart progenitor and cranial neural crest cell lines isolated using the ACTCellerate technology will be presented.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com.
Forward-Looking Statements
Posted by invester on :
Here it is. This is a $10-$20 stock masked as a .87. With under 30 million shares out., do the math. This is the best stock out there.
Dr. West will discuss ACT's recently-published data on blastomere biopsy (a novel technique that allows human ES cell lines to be produced from a single embryonic cell), thereby demonstrating the feasibility of producing new human ES cell lines without disaggregating human embryos.
Posted by bilgert on :
WASHINGTON (Reuters) - Injecting human embryonic stem cells into the brains of Parkinson's disease patients may cause tumors to form, U.S. researchers reported on Sunday.
Steven Goldman and colleagues at the University of Rochester Medical Center in New York said human stem cells injected into rat brains turned into cells that looked like early tumors.
Writing in the journal Nature Medicine, the researchers said the transplants clearly helped the rats, but some of the cells started growing in a way that could eventually lead to a tumor.
Various types of cell transplants are being tried to treat Parkinson's disease, caused when dopamine-releasing cells die in the brain.
This key neurotransmitter, or message-carrying chemical, is involved in movement and Parkinson's patients suffer muscle dysfunction that can often lead to paralysis. Drugs can slow the process for a while but there is no cure.
The idea behind brain cell transplants is to replace the dead cells. Stem cells are considered particularly promising as they can be directed to form the precise desired tissue and do not trigger an immune response.
Goldman's team used human embryonic stem cells. Taken from days-old embryos, these cells can form any kind of cell in the body. This batch had been cultured in substances aimed at making them become brain cells.
Previous groups have tried to coax stem cells into becoming dopamine-releasing cells.
Goldman's team apparently succeeded and transplanted them into the rats with an equivalent of Parkinson's damage. The animals did get better.
But the grafted cells started to show areas that no longer consisted of dopamine-releasing neurons, but of dividing cells that had the potential to give rise to tumors.
The researchers killed the animals before they could know for sure, and said any experiments in humans would have to be done very cautiously.
Scientists have long feared that human embryonic stem cells could turn into tumors, because of their pliability.
Opponents of embryonic stem cell research cite such threats. Many opponents, including President George W. Bush and some members of Congress, believe it is immoral to destroy human embryos to obtain their stem cells.
Posted by invester on :
ACTC has done it. Look at the money one state is trying to raise, and look at his key issue. Not damaging the embryo. ACTC has a patent on it. Love it.
In Wisconsin, stem cells are a central issue in a tight gubernatorial race. Democratic Gov. Jim Doyle is pushing to raise more than $750 million in public and private funding for stem-cell research facilities to augment those in Madison. Doyle's GOP challenger, U.S. Rep. Mark Green, has called for more than $25 million to study whether viable cells can be extracted without destroying embryos.
Posted by IMAKEMONEY on :
Business Wire via COMTEX
Oct 24, 2006 9:30:37 AM
Dr. Lanza to be honored at 11th Annual Mass High Tech All-Star Awards Networking Celebration
WORCESTER, Mass., Oct 24, 2006 (BUSINESS WIRE) --
One of the world's leading authorities on embryonic stem cells, Robert Lanza, M.D., VP, Research and Scientific Development for Advanced Cell Technology, Inc. (OTCBB: ACTC) will be honored at the 11th Annual Mass High Tech All-Star Awards Networking Reception, October 25th from 6:00-8:30pm at the Westin Boston Waterfront Hotel.
Robert Lanza, M.D., has over 30 years of medical research experience, and has authored/edited 18 books, including "Essentials of Stem Cell Biology" and the "Handbook of Stem Cells" (as Editor-in-Chief). Last month, Dr. Lanza served as senior author for a paper that appeared in the journal Cloning and Stem Cells, in which ACTC scientists and their collaborators rescued visual function in animals using retinal pigment epithelial cells (RPE) derived from human embryonic stem (hES) cells. In August, Dr. Lanza served as senior author of a paper in Nature, describing a method for deriving stem cells using a single-cell approach that does not harm embryos.
He is a former Fulbright Scholar, and studied as a student in the laboratory of Jonas Salk (The Salk Institute), Richard Hynes (MIT), and Nobel laureates Gerald Edelman (Rockefeller University) and Rodney Porter (Oxford University). He also worked closely (and coauthored a series of papers) with the late Harvard psychologist B.F. Skinner and heart transplant pioneer Christiaan Barnard. Dr. Lanza received his undergraduate and medical degrees from the University of Pennsylvania, where he was both a University Scholar and Benjamin Franklin Scholar.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com..
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 or Media: Bill Douglass, 212-825-3210
Copyright Business Wire 2006
Posted by invester on :
This is crazy. Look at the market cap.
DIRECT COMPETITOR COMPARISON
ACTC.OB GERN STEM Industry Market Cap: 20.35M 508.11M 214.66M 636.35M
Posted by IMAKEMONEY on :
Related Quotes Sym. Price Chg. ACTC Trade News 0.77 0 Advanced Cell Technology to Present Stem Cell Programs at Rodman & Renshaw`s Annual Healthcare Conference in New York
November 03, 2006 12:51:26 (ET)
ALAMEDA, Calif., Nov 03, 2006 (BUSINESS WIRE) -- Advanced Cell Technology (ACTC), Inc. (ACTC, Trade), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, today announced that Chief Executive Officer, William M. Caldwell, IV will be a featured presenter at Rodman & Renshaw's 8th Annual Healthcare Conference in New York City on November 6-8.
Mr. Caldwell will review ACTC's proprietary technologies and recent milestones in its mission to drive medically needed stem cell-based therapies to the clinic. He will discuss ACTC's stem cell-related technology platforms, and will spotlight the company's lead programs to develop novel stem cell therapies in the fields of vision, cardiovascular disease and dermal wound repair for scarless healing from burns, surgery and other causes.
ACTC's recent milestones include publication of the company's single cell blastomere technique for generating new embryonic stem cell lines without harming the embryo's potential for life and development. The Company also recently published positive progress in its retinal pigment epithelial (RPE) program, a therapeutic development initiative to develop stem cell-based treatment for certain diseases of the retina.
The Rodman & Renshaw conference will feature presentations from over 300 companies representing the medical device, pharmaceutical and biotechnology industries.
The conference will take place at the Palace Hotel at 455 Madison Ave., in New York, NY. The ACTC presentation is scheduled for 11:40 AM in the Kennedy II room, 4th floor.
Advanced Cell Technology Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210 or Financial Communications Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com Copyright Business Wire 2006
Set Alerts
Create your Personalized SmartAlerts here.
Quotes
To get interactive quotes within this page, download Flash now
Posted by IMAKEMONEY on :
Web Alert: Advanced Cell Technology Presents Stem Cell Technologies and Programs Today at Rodman & Renshaw Healthcare Conference in New York
November 06, 2006 06:30:09 (ET)
ALAMEDA, Calif., Nov 06, 2006 (BUSINESS WIRE) -- Advanced Cell Technology (ACTC), Inc. (ACTC, Trade), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, will present an overview of its stem cell-based therapeutic development programs and proprietary technologies today at the Rodman & Renshaw 8th Annual Healthcare Conference in New York City.
A live webcast of the presentation, by Chief Executive Officer William M. Caldwell, IV, will also be accessible online during the presentation and archived for 90 days. Details of the conference presentation and webcast are below.
WHAT: ACTC Presentation at Rodman & Renshaw 8th Annual Healthcare Conference WHO: Chief Executive Officer William M. Caldwell, IV WHEN: Today, November 6, 2006, at 11:40 a.m. EST. WHERE: Kennedy II Room, 4th Floor, Palace Hotel, 455 Madison Ave., New York, NY WEBCAST: An online webcast of the presentation will be accessible at www.advancedcell.com. ARCHIVE: A downloadable copy of the presentation will also be available on the Company's website at www.advancedcell.com/conference-presentations/. In the presentation, Mr. Caldwell will spotlight the company's technologies and programs to develop novel stem cell therapies in the fields of vision, cardiovascular disease and dermal wound repair for scarless healing from burns, surgery and other causes.
The Rodman & Renshaw conference will feature presentations from over 300 companies representing the medical device, pharmaceutical and biotechnology industries.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Mass.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group James Carbonara, Investors, 212-825-3210 Bill Douglass, Media, 212-825-3210 or Financial Communications Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com Copyright Business Wire 2006
Posted by IMAKEMONEY on :
Advanced Cell Technology to Present at the 2006 PIPES Conference on November 7th
November 06, 2006 08:43:08 (ET)
ALAMEDA, Calif., Nov 06, 2006 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.'s (ACTC, Trade) William M. Caldwell, IV, Chief Executive Officer and Michael D. West, Ph.D., President and Chief Scientific Officer, will present at the 2006 PIPES Conference at the Waldorf Astoria Hotel, on Tuesday, November 7th, 2006. Mr. Caldwell will present at 1:30pm. Dr. West will be giving a scientific update at 2:00 and 2:30pm.
Advanced Cell Technology Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210 or Financial Communications: Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com Copyright Business Wire 2006
Posted by mlfox on :
Looks to be getting a bit of a run this morning.
up 12% Posted by IMAKEMONEY on :
GONNA GO!!!
Posted by mlfox on :
OK -- made some money, need a new entry Posted by invester on :
This is huge, the Dems. may take the Senate as well. I now have 30k. .
Posted by liberty01 on :
i forgot about this page! ACTC no Brainer with Dems in. Ive been slowly adding since the .70's. Sorry for not posting in the .11 and up since then. Im ready for a fun ride, wait till everyone else gets the same idea!!!!! WHOOT WHOOOT!
Posted by invester on :
My D.C.A. is .71. This is an $8-$10 stock with only 27 million shares out.
Posted by HossTrader on :
It is getting hard not to want to add more now. LOL
Posted by IMAKEMONEY on :
VOTING WENT WELL FOR THIS ONE,JMO Posted by invester on :
Indeed it did.
Posted by IMAKEMONEY on :
Meanwhile, Merck & Co. (MRK, Trade ) saw its shares fall 3.5% to $44.29. The drugmaker and Dow Jones Industrial Average component said late Tuesday that it's facing up to $5.58 billion in tax liabilities in the U.S. and Canada and that it plans to contest the matter with the two nations' tax authorities.
While most of the drug industry traded downward amid uncertainty what a change in control in at least one chamber on Capitol Hill will mean, stem-cell research companies rallied on the election results.
Several key members of the Republican leadership in Washington have been against lifting certain funding restrictions on organizations that conduct stem-cell research on human embryos. President Bush issued the only veto of his term in office earlier this year of a bill that would have encouraged embryonic stem-cell research.
"I hope and expect that these bills will re-emerge early in the next session," Advanced Cell Technology's chief executive officer, William Caldwell, told MarketWatch Thursday.
Advanced Cell Technology (ACTC, Trade ) shares were up 15% at 93 cents a share
Posted by IMAKEMONEY on :
Advanced cell Tech up .12 on heels of pro Stem cell research Democrats house take over.
ACTC 0.93 0.12
Advanced Cell Technology Scientist Dr. Robert Lanza Invited to Address The National Academy of Sciences at Stem Cell Policy Meeting Advanced Cell Technology, Inc. (ACTC) (OTCBB:ACTC), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, announced today that Dr. Robert Lanza, Vice President of Research and Scientific Development of ACTC, will present before the National Academy of Sciences (NAS) at a special meeting to explore the latest developments in embryonic stem cell science and policy.
Dr. Lanza will make his presentation at the NAS's meeting of the Human Embryonic Stem Cell Research Advisory Committee, scheduled for November 7-8 in Washington, D.C. The meeting is dedicated to the furtherance of stem cell science and technology. His presentation will focus on ACTC's single-cell blastomere technique, which the company developed to derive new stem cell lines while preserving the embryo's potential for life and normal development.
The NAS, a prestigious society of distinguished scholars engaged in scientific research, has recruited Dr. Lanza to provide expert advice as they explore alternative ways to derive stem cells and make recommendations for the nation's public policy officials.
"We believe ACTC's technique for deriving stem cells without harming the embryo's potential for life can be an important consideration for the NAS as they form their recommendations to public officials," said William M. Caldwell IV, Chief Executive Officer of Advanced Cell Technology.
Advanced Cell Technology recently announced that company scientists demonstrated the ability to generate new human embryonic stem cell lines by adapting a proven technique already used at in vitro fertilization labs to determine genetic health. The ACTC approach maintains the embryo's potential for life, addressing one of the key debates in stem cell research.
ACTC's mission is to develop stem cell based treatments and therapies for a broad range of disease and injuries. Embryonic stem cells promise to provide a well-characterized and reproducible source of replacement tissue for human clinical studies. One of ACTC's lead development programs applies human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) for the treatment of retinal degenerative diseases such as macular degeneration and retinitis pigmentosa. Another development program focuses on the use of hESC-derived hemangioblasts for vascular restoration of organs and limbs.
Since 1863, the nation's political leaders have often turned to the NAS for advice on the scientific and technological issues that frequently pervade policy decisions. Most of the NAS's science policy and technical work is conducted by its operating arm, the National Research Council, created expressly for this purpose. These non-profit organizations provide a public service by working outside the framework of government to ensure independent advice on matters of science, technology, and medicine.
Dr. Lanza will be speaking at 10:30 a.m. on Nov. 7. A live audio webcast of the event, along with Dr. Lanza's PowerPoint presentation, will be available at www.advancedcell.com.
About Advanced Cell Technology, Inc.
Advanced Cell Technology Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information, please visit: www.advancedcell.com.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Posted by HossTrader on :
Loving this company. Monkey, I might break my own rules and hold a chunk long term on this one.
Posted by IMAKEMONEY on :
SAME HERE HOSS.
Posted by IMAKEMONEY on :
Related Quotes Sym. Price Chg. ACTC Trade News 0.915 0 Advanced Cell Technology Names Current Chief Executive Officer William M. Caldwell IV as Chairman of the Board
Nov 9, 2006 06:30:26 (ET)
ALAMEDA, Calif., Nov 09, 2006 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, today announced that current Chief Executive Officer, William M. Caldwell IV, has been appointed to serve as the Chairman of the Board in a unanimous vote by the company's directors.
Mr. Caldwell will assume the role of Chairman from Dr. Michael D. West, who will continue in his role as President, Chief Scientific Officer and a director of Advanced Cell Technology. Dr. West, a recognized leader in the fields of embryonic stem cell science and regenerative medicine, will continue his focus on and commitment to ACTC's research and development programs.
"I want to thank Dr. West for his leadership at Advanced Cell Technology during his service as Chairman of the Board. We are all grateful for his current and continuing contributions," said Mr. Caldwell. "My role as CEO with ACTC's business and scientific teams has been extremely rewarding, and I welcome the Board's support in their decision to expand my duties to the position of Chairman."
About Advanced Cell Technology, Inc.
Advanced Cell Technology Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210 or Financial Communications Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com
Posted by IMAKEMONEY on :
Advanced Cell Technology Names Current CEO William M. Caldwell IV As Chmn Of The Bd>ACTC
Nov 9, 2006 06:33:00 (ET)
(MORE TO FOLLOW) Dow Jones Newswires
November 09, 2006 06:30 ET (11:30 GMT)
Posted by The SiLK on :
Down early but may be rebounding
Posted by juice on :
i want in on actc just having thrown money at it yet
Posted by Balttrader on :
I bought in at $.90...Company looks unusually promising for an otc. Could be quite a play!
Posted by juice on :
i got 4k at .85 today. hopefully ill have to average up (a lot), not average down:) this one could be the bigg one someday. im goin longggggggggg
Posted by Balttrader on :
Besides the fact that this company is sound from a fundamental standpoint, it also looks terrific from a technical perspective...over the month it has formed a pretty nice looking triangle pattern, with higher lows and a horizontal top. These formations usually indicate an outbreak to the upside.
Posted by juice on :
well now that i finally got in im watchin L2's more, over 150k traded at bid SBSH sitting there, not budging...
Posted by Balttrader on :
Stock will bounce off the bottom of the triangle formation, this week should all be green days! IMO
Posted by T e x on :
quote:Originally posted by Balttrader: Stock will bounce off the bottom of the triangle formation, this week should all be green days! IMO
kewl...
think I'll follow that projection.
you're saying it *will* bounce, no doubt?
Posted by 10of13 on :
IMO.. just a little more down before any bounce...
Posted by Balttrader on :
I'll stand by my prediction but just in case it is a red day she wont close below .81 IMO
Posted by Balttrader on :
Looks like I was correct in regards to it being a green day... up 4.24% as of right now!
Posted by 10of13 on :
Yes you were! Good call...
quote:Originally posted by Balttrader: Looks like I was correct in regards to it being a green day... up 4.24% as of right now!
Posted by Balttrader on :
Tuesday close over .90
Posted by IMAKEMONEY on :
Advanced Cell Technology Comments on the Results of the Midterm Elections
Nov 14, 2006 09:41:20 (ET)
ALAMEDA, Calif., Nov 14, 2006 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) Chairman and CEO William Caldwell today commented on the midterm United States Congressional elections held Tuesday, November 7, 2006. "Embryonic stem cells hold the potential to provide a well-characterized and reproducible source of replacement cells for clinical studies and the treatment of devastating diseases and injuries such as heart disease, cancer, macular degeneration, Parkinson's disease, Alzheimer's disease, and diabetes. We have been encouraged by our progress to date, though there is little doubt that in the United States progress in our field has been hampered by the ban on federal funding of research on new embryonic stem cell lines. I believe the changing political tide brings us yet another step closer to federal funding for embryonic stem cell research and ultimately to developing therapies for devastating and life threatening indications."
Advanced Cell Technology strongly supported both H.R. 810 and S. 2754, which were legislative efforts put before Congress in July 2006 to support the use of federal funds to research frozen hESC lines and to promote medical research and development of alternative hESC lines through techniques that do not harm a human embryo or fetus.
"While we were disappointed that H.R. 810 and S. 2754 were not enacted into law, we have been encouraged by the bipartisan support of recent legislative efforts to provide federal funding for embryonic stem cell research," Mr. Caldwell continued. "We are also encouraged by the widespread support of embryonic stem cell research by the American public as evidenced by the results of the recent Congressional elections. It may be only a matter of time before the federal government provides the expanded funding that scientists in laboratories in universities at pharmaceutical and biotechnology companies across the country require to move novel therapies from the lab to the clinic and, ultimately, to the bedside. Eventually, this funding could accelerate the programs for companies researching both embryonic and adult stem cell therapies including but not limited to Advanced Cell Technology, Geron Corporation, StemCells Inc., and Aastrom Biosciences. We will continue to work with our technological, ethical, and legislative partners to focus on driving therapies to the clinic."
Advanced Cell Technology's recent milestones include publication of the company's single cell blastomere technique for generating new embryonic stem cell lines without harming the embryo's potential for life and development. The company also recently published positive progress in its retinal pigment epithelial (RPE) program, a therapeutic development initiative to develop stem cell-based treatment for certain diseases of the retina. Advanced Cell Technology also continues to investigate the use of human embryonic stem cell-derived hemangioblasts for vascular restoration of organs and limbs.
About Advanced Cell Technology, Inc.
Advanced Cell Technology Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210 or Financial Communications Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com
Posted by Balttrader on :
Today's candle pierces the support level...not sure what to think
Posted by Balttrader on :
Actully this may bounce off the low level of resistance at .775. Won't get concerned unless it pierces that low point.
Posted by IMAKEMONEY on :
Companies Notifying SEC Of Late Reports -5- -2-
Nov 16, 2006 14:02:00 (ET)
WASHINGTON (Dow Jones)--Companies and other entities that are unable to file their quarterly and annual reports on time must notify the Securities and Exchange Commission. A deadline for many larger-capitalization companies to file quarterly reports was Nov. 9; another deadline was Tuesday.
The following companies, listed alphabetically, submitted late-filing notifications or amended those notifications this week. A U.S. stock exchange ticker symbol or CIK number is provided.
Posted by IMAKEMONEY on :
all pharms/biotechs ALWAYS have huge losses. its the nature of that beast. ACTC will have to drop to a bottom begore I ever tie up my money in this snail.
Posted by RichBy26 on :
why is this moving today??? up quite a bit. LOD .73 now at .85...
Posted by IMAKEMONEY on :
YEP, VERY NICE AND IM LOADED UP WITH IT,LOL
Posted by RichBy26 on :
any guess about the large swing?
Posted by IMAKEMONEY on :
THIS COMPANY COULD GO TO 5 TO 10 BUCKS IN A DAY WITH THE RIGHT NEWS,JMO, RICH26 READ THE THREAD. Posted by IMAKEMONEY on :
New York Times Cites Advanced Cell's Review in Nature On an Approach to Generate Human Embryonic Stem Cells Without Destroying the Embryo
Nov 24, 2006 08:33:07 (ET)
ALAMEDA, Calif., Nov 24, 2006 (BUSINESS WIRE) -- The New York Times has commented on Advanced Cell Technology, Inc's (ACTC, Trade ) review in Nature surrounding its approach to generate human embryonic stem cells without destroying the embryo, stating, "the Journal affirmed the report's scientific validity."
The paper has been published in hard copy along with a supplement and addendum in the November 23, 2006 print issue of Nature, and demonstrates that single blastomeres can be used to establish human embryonic stem cell lines. The paper was originally published online in Nature, in August 2006.
The technique is modeled on PGD (pre-implantation genetic diagnosis), an approach for single-cell biopsy using micromanipulation that does not interfere with the developmental capacity of the parent embryo.
The following link may be used to access the full New York Times article, commenting on the Nature paper.
http://www.nytimes.com/2006/11/22/science/23stemcnd.html?hp&ex= 1164258000&en=13d6158df8d9e8b1&ei=5094&partner=homepage(Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
About Advanced Cell Technology, Inc.
Advanced Cell Technology Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210 Or Financial Communications: Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com
Posted by Mortimer on :
Good volume today so far especially for this Friday. Hopefully that New York Times article was the "all aboard" call. I've been settled in my seat and patiently waiting for this train to leave the station. Looking forward to see what happens on Monday after more people get back to their seats.
Posted by IMAKEMONEY on :
NEW YORK, Nov 29, 2006 (BUSINESS WIRE) -- The New York Society of Security Analysts (NYSSA) will present the 10th Annual Biotech/Specialty Pharma Conference on December 12 to 13, 2006.
What does the future have in store for the biotech industry? Don't miss this chance to hear Michael D. West, PhD, president of Advanced Cell Technology and author of The Immortal Cell: One Scientist's Quest to Solve the Mystery of Human Aging, discuss the emerging field of stem cell research. Other presentations include companies focused on hormone therapy, drug delivery and treatments for HIV/AIDS and cancer.
The following companies are presenting on day one:
Aradigm Corporation (ARDM, Trade ); BioSante Pharmaceuticals, Inc. (BPA, Trade ); CytRx Corporation (CYTR, Trade ); DNAPrint Genomics, Inc. (DNAG, Trade ); DRAXIS Health Inc. (DRAX, Trade ); DURECT Corporation (DRRX, Trade ); Heska Corporation (HSKA, Trade ); The Immune Response Corporation (IMNR, Trade ); Viral Genetics, Inc. (VRAL, Trade ); and Xechem International, Inc. (XKEM, Trade ).
The following companies are presenting on day two:
Advanced Cell Technology, Inc. (ACTC, Trade ); Cleveland BioLabs, Inc. (CBLI, Trade ); Cyclacel Pharmaceuticals, Inc. (CYCC, Trade ); EntreMed, Inc. (ENMD, Trade ); Neuro-Hitech Pharmaceuticals, Inc. (NHPI, Trade ); Provectus Pharmaceuticals, Inc. (PVCT, Trade ); The Quigley Corporation (QGLY, Trade ); and XTL Biopharmaceuticals Ltd. (XTLB, Trade ).
The conference will be held on December 12, 2006, 8:30 a.m. to 5:10 p.m., and December 13, 2006, 8:30 a.m. to 4:30 p.m. at NYSSA, 1177 Avenue of the Americas, 2nd Floor, NYC. Registration deadline is December 5, one day, $265 NYSSA members, $365 nonmembers; two days, $365 NYSSA members, $465 nonmembers. No charge for press with credentials. A complete agenda is available at
(Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
About NYSSA
NYSSA, established in 1937, is the premier independent forum for the exchange of information among investment decision-makers. A not-for-profit educational organization with over 9,500 members, NYSSA is committed to the promotion of best practices and the highest professional and ethical standards in the investment industry. NYSSA is the largest of the more than 134 societies worldwide that make up CFA Institute, which has more than 83,000 members.
SOURCE: The New York Society of Security Analysts
The New York Society of Security Analysts Dawn Cavalieri, 212-541-4530, ext. 20 press*nyssa.org
Posted by IMAKEMONEY on :
Advanced Cell Technology's Robert Lanza, M.D., to Deliver Keynote Address at the University of Florida's Vision Research Symposium on December 7, 2006
Dec 7, 2006 08:33:15 (ET)
ALAMEDA, Calif., Dec 07, 2006 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.'s (ACTC, Trade ) Robert Lanza, M.D., VP of Research and Scientific Development, will deliver the keynote address at the University of Florida's Vision Research Symposium, titled "Advances in the Use of Stem Cells for Repair and Regeneration of the Eye," December 7, 2006, at 12:10 PM, at the Hilton University of Florida Conference Center, Gainesville, Florida. Dr. Lanza's presentation is titled "The Use of Embryonic Stem Cells in Regenerative Medicine." The recent progress that has been made in using embryonic stem-cell derived cells to rescue visual function in animals will be discussed, as well as the scientific promise --and challenges -- that remain before these and other human stem cell therapies can enter the clinic.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 or Media: Bill Douglass, 212-825-3210 or Financial Communications: Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com
Posted by IMAKEMONEY on :
Advanced Cell Technology Executives to Present Keynote Address and Company Presentation at New York Society of Security Analysts (NYSSA) Conference
Dec 11, 2006 08:32:25 (ET)
ALAMEDA, Calif., Dec 11, 2006 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.'s (ACTC, Trade ) Michael West Ph.D., President and Chief Scientific Officer, will deliver the keynote luncheon speech at the New York Society of Security Analysts Conference (NYSSA), on December 12, 2006 at 12:30 PM. William M. Caldwell, IV, Chief Executive Officer, will deliver the company presentation on December 13, 2006 at 1:40 PM. The conference is being held at the NYSSA headquarters located at 1177 Sixth Avenue in New York.
Widely regarded as a leader in the field, prior to founding ACTC, Dr. West organized and managed the research between Geron Corporation (GERN, Trade ) and its academic collaborators, James Thomson and John Gearhart, that led to the first isolation of human embryonic stem and human embryonic germ cells. Dr. West will be speaking on the "Emerging Field of Stem Cells".
William Caldwell will be delivering the company presentation, highlighting Advanced Cell's leadership and advancement in the stem cell field. The company recently published a paper in Nature regarding the use of embryonic stem cells to rescue visual function in animals, and in August announced an approach to generate human embryonic stem cells that does not destroy the embryo.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210 or Financial Communications: Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com
Posted by IMAKEMONEY on :
Advanced Cell Technology Invited to Deliver Keynote Address at Prestigious International Stem Cell Therapy and Regenerative Medicine Conference in London
Dec 13, 2006 06:30:34 (ET)
ALAMEDA, Calif., Dec 13, 2006 (BUSINESS WIRE) -- Advanced Cell Technology (ACTC), Inc. (ACTC, Trade ), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, announced today that William Caldwell IV, Chairman and Chief Executive Officer, has been invited to present an overview of the Company's proprietary stem cell science and therapeutic programs at the upcoming 4th Annual Commercialization of Tissue Engineering and Cell Therapy, to be held December 14 and 15, 2006, in London.
The conference is designed to bring together research, academic and business leaders who are driving progress in cell-based sciences and industry. Attendees and speakers will address fundamental challenges and opportunities of producing cell-based therapies, with a focus on the strategic path to bring products to market.
In his keynote address, Mr. Caldwell will discuss ACTC's unique technologies as well as its overall strategies for developing medically valuable therapies for a number of market segments in medicine and health care. ACTC has pioneered a range of innovations relating to human embryonic stem cells, and is committed to taking a leadership role in the development of stem cell based therapies to cure or treat a range of serious diseases, injuries and degenerative medical conditions.
Mr. Caldwell's presentation is scheduled for December 15, 2006, at 9:10 am GMT. The conference will be held at the Grange Holborn Hotel in London.
"I believe that we are at a pivotal point in our industry's evolution, where research has begun to show the vast potential of stem cell-based therapies to offer important advances in medical care," said Mr. Caldwell. "At ACTC, we are already employing innovative solutions in both basic science as well as product applications, and I look forward to sharing our ideas with my colleagues in the extended international community of scientists and business leaders."
ACTC's mission is to develop stem cell based treatments and therapies for a broad range of disease and injuries. Embryonic stem cells promise to provide a well-characterized and reproducible source of replacement tissue for human clinical studies. One of ACTC's lead development programs applies human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) for the treatment of retinal degenerative diseases such as macular degeneration and retinitis pigmentosa. Another development program focuses on the use of hESC-derived hemangioblasts for vascular restoration of organs and limbs.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210 or Financial Communications Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com
![[Big Grin]](biggrin.gif)
![[Smile]](smile.gif)
![[Wink]](wink.gif)
![[Eek!]](eek.gif)